Getting to Know Exosomes
What exosomes are, where they come from, and why scientists went from calling them "cellular trash" to the biggest breakthrough in regenerative medicine.
▶ Watch: Exosomes EXPLAINED- Exosomes are microscopic parcels cells use to communicate
- Discovered in the 1980s — initially thought to be cellular waste
- Now understood as a key mechanism for cell-to-cell signaling
- Biotech companies are using them to deliver medicine
The Celebrities Using Exosomes
Why Kim Kardashian, Jennifer Aniston, Gwyneth Paltrow, and Bryan Johnson are spending thousands on exosome therapies — and why that means your prospects' patients are asking for it.
▶ Watch: Hollywood Stars & Exosomes- Kim Kardashian, Jennifer Aniston use exosomes for skin rejuvenation
- Gwyneth Paltrow called it "one of the most exciting innovations in skincare"
- Bryan Johnson: exosome therapy is his "favorite skin therapy for 2024"
- Market demand angle: patients ask clinics for what celebrities use
- Bonus: The Piazza Center (an active lead) wrote the article on this
What We Actually Sell
The four products: Matrix (our main exosome product), Alocyte (premium stem cell + exosome), Nasal Spray, and Eye Drops. What each one is, when clinics use it, and how to remember them.
| Product | What it is | Price |
|---|---|---|
| Matrix | Exosomes (main product) | $430 – $1,720 |
| Alocyte | Stem cells + exosomes (premium) | $3,225 |
| Nasal Spray | Exosomes through the nose | $1,075 |
| Eye Drops | Exosomes for the eyes | $1,290 |
- Matrix = exosomes (most common, most versatile)
- Alocyte = exosomes + stem cells (premium option)
- Nasal spray and eye drops = specialized delivery methods
- You don't need to memorize prices — just know Matrix is main, Alocyte is premium
The 30-Second Pitch
How to explain what we do to a clinic in 30 seconds — without jargon, without science, and without sounding like a sales pitch.
Objection Handling: "We Already Have a Supplier"
The number one objection you'll hear and how to handle it without being pushy.
Objection Handling: "Too Expensive"
How to talk about pricing without discounting, and why being a second source is a value proposition.
The Follow-Up Sequence
How to follow up without being annoying. The 6-touch cadence and when to use each touch.
Closing: Getting the First Order
How to move from "we'll think about it" to an actual order. Trial sizes, first-order incentives, and removing friction.